Aldeyra Therapeutics Inc ALDX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Aldeyra Therapeutics Announces Intent to Submit Formal Dispute Resolution Request for Reproxalap to Treat Dry Eye Disease
-
Aldeyra Therapeutics to Host Regulatory Update Webcast
-
Aldeyra Therapeutics Shares Fall as Drug Rejected by Regulator on Efficacy Concerns
-
Aldeyra Shares Fall Premarket After FDA Extends Reproxalap Review
Trading Information
- Previous Close Price
- $0.92
- Day Range
- $0.88–0.97
- 52-Week Range
- $0.86–5.93
- Bid/Ask
- $0.97 / $1.03
- Shares Outstanding
- 60.33M
- Market Cap
- $57.83M
- Volume/Avg
- 218 / 1M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 6
- Website
- https://www.aldeyra.com
Valuation
|
Metric
|
ALDX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.53 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ALDX
|
|---|---|
Quick Ratio | 4.67 |
Current Ratio | 4.91 |
Interest Coverage | −16.95 |
Quick Ratio
ALDX
Profitability
|
Metric
|
ALDX
|
|---|---|
Return on Assets (Normalized) | −26.84% |
Return on Equity (Normalized) | −40.92% |
Return on Invested Capital (Normalized) | −33.90% |
Return on Assets
ALDX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|R#@bNZ | LOCK|r^gMD | $128B | |||
| Moderna Inc
MRNA
| LOCK|JNZkZmL | LOCK|<g! | $78B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|qx>mt! | LOCK|^b%YY | $76B | |||
| argenx SE ADR
ARGX
| LOCK|pSX?V! | LOCK|#?& | $59B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|<!ZRfb | LOCK|rg | $42B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|^MHlc@v | LOCK|RT^& | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|x!!>#!? | LOCK|mZ@>h | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|b?$T&$^ | LOCK|^R | $24B | |||
| Incyte Corp
INCY
| LOCK|c?%?Vn | LOCK|&x | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|$G<x?^ | LOCK|^dk | $15B |
United States